Symposium - European Medical Journal

Continue

Symposiums

Neurology
15 Aug 2023

Retracted: A Spotlight on Friedreich Ataxia: Optimising the Patient Journey from Diagnosis to Disease Management

This article has now been retracted and a retraction statement has been published.
Neurology
6 Mins
15 Aug 2023

Development of the Clinical Myotonia Rating Scale and a Mexiletine Prescribing and Monitoring Algorithm for Patients with Non-Dystrophic Myotonia

In the rare neuromuscular disorders classed as NDM, muscle stiffness (myotonia) is the major symptom and is defined by a delayed muscle…
Neurology
8 Mins
15 Aug 2023

Mitochondrial DNA Maintenance Disorders: Impact of Impaired Deoxynucleoside Triphosphates Metabolism

The maintenance of mitochondrial DNA (mtDNA) is dependent upon several nuclear gene-encoded proteins including enzymes forming the…
Hepatology
9 Mins
3 Aug 2023

Management of Cholestatic Pruritus in Primary Biliary Cholangitis: Ileal Bile Acid Transporter Inhibition and Holistic Care

Symptoms of the progressive cholestatic liver disease primary biliary cholangitis (PBC) include pruritus and fatigue.
Hematology
9 Mins
1 Aug 2023

What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment Options for Transplant-Ineligible Patients

DLBCL accounts for approximately 30% of non-Hodgkin’s lymphomas diagnosed each year. Initially, DLBCL is generally treated…
Respiratory
12 Mins
28 Jul 2023

Aiming for Clinical Remission in Asthma: The Next Frontier

For many people living with asthma, medications such as inhaled corticosteroids (ICS) and short- or long-acting β agonists…
Nephrology
10 Mins
27 Jul 2023

Filling the Gap by Targeting the Gut: First Disease-Modifying Treatment Approved for IgA Nephropathy

Bengt Fellström, Uppsala University, Sweden, described the relationship between IgA nephropathy (IgAN) and gastrointestinal mucosal…
Nephrology
5 Mins
27 Jul 2023

Proteinuria as a Surrogate Endpoint for Disease Progression in IgA Nephropathy: Predicting Long-Term Treatment Effects of Sparsentan

IgA nephropathy (IgAN) is a rare, life-limiting disease for which there is significant unmet need. Until recently, drug development for…
We’ve noticed you’re accessing
from North/South America.